OClawVPS.com
RayzeBio
Edit

RayzeBio

https://rayzebio.com/
Last activity: 16.06.2025
Active
Categories: BioTechDevelopmentDrugResearch
Leader in targeted radiopharmaceuticals to improving cancer patient survival. Broad pipeline of innovative drugs against solid tumor targets
Followers
7.89K
Mentions
109
Location: United States, California, San Diego
Employees: 51-200
Total raised: $373.53M
Founded date: 2020
Facebook
LinkedIn
Email

Investors 5

Funding Rounds 3

DateSeriesAmountInvestors
14.09.2022Series D$160M-
07.08.2021Series C$108.53M-
14.12.2020Series B$105M-

Mentions in press and media 109

DateTitleDescription
18.06.2025The Dawn of Radioligand Therapies: A New Era in Precision OncologyIn the realm of cancer treatment, innovation is the lifeblood that fuels hope. The latest beacon of this hope shines brightly on radioligand therapies (RLTs). These therapies are not just a whisper of potential; they are a clarion call for ...
16.06.2025Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision OncologyNew Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global ...
15.05.2025Vivo Capital: Public Fund Closed With Over $740 Million In CommitmentsVivo Capital—a leading global investment firm focused exclusively on healthcare and life sciences—announced it has closed the third cycle of its Vivo Opportunity Fund and its affiliates with over $740 million in commitments. The Public Fund...
06.05.2025Bristol Myers to invest $40 billion in the US over 5 yearsBristol Myers to invest $40 billion in the US over 5 years By ReutersMay 5, 202510:37 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link Test tubes are seen in front of a displayed Bristol Myers Sq...
19.09.2024Радиофармацевтические препараты назвали прорывом в борьбе с ракомПроизводители лекарств делают ставку на то, что доставка радиации непосредственно к опухолям станет следующим большим прорывом в борьбе с раком. Bristol Myers Squibb, AstraZeneca, Eli Lilly и другие фармацевтические компании потратили около...
13.06.2024The Lustgarten Foundation Appoints Two New Board MembersTo date, the foundation has invested more than $282M in high-risk, high-reward research to accelerate and expand life-saving treatment options. Richard Barakat, MD, and Aaron Kantoff join the Lustgarten Foundation Board of Directors WOODBUR...
19.03.2024AstraZeneca Joins Radiopharma Deals Spree With $2B Fusion AcquisitionAstraZeneca is following in the footsteps of some of its big pharmaceutical company peers, plunking down $2 billion to acquire its radiopharmaceuticals partner Fusion Pharmaceuticals. More than adding a pipeline of targeted radiation therap...
15.09.2023RayzeBio Announces Pricing of Upsized $311 Million Initial Public Offering-
25.08.2023RayzeBio plans IPO to push radiotherapy 'pipeline-in-a-product' through phase 3RayzeBio has already persuaded investors to hand over more than $400 million to pursue its targeted radiation approach to treating cancer. Now, with its lead product in phase 3 trials, the biotech is eyeing up an IPO to push its plans forwa...
31.03.2023Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater ChinaSHANGHAI, March 31, 2023 /PRNewswire/ -- Ablaze Pharmaceuticals, a biotech company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients in China, today announced the development plans of a first-in-class nove...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In